Abbott Labs Financials
This page shows Abbott Labs (ABT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Abbott's recent story is earnings normalization masking a steady cash engine and a quieter shift toward a lower-debt balance sheet.
FY2024's profit surge was not mirrored by operating margin or cash flow, and FY2025 net income fell back to$6.5B even as operating cash flow rose to$9.6B . That makes cash generation, not headline earnings, the cleaner read on the business: the operating engine stayed comparatively steady while reported earnings swung around the tax line, so the apparent FY2025 profit drop overstates the change in underlying operations.
The business rebuilt gross margin after the FY2023 dip, reaching
Abbott's balance-sheet posture has become more conservative, with long-term debt reduced from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Abbott Labs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Abbott Labs has an operating margin of 18.2%, meaning the company retains $18 of operating profit per $100 of revenue. This results in a moderate score of 60/100, indicating healthy but not exceptional operating efficiency. This is up from 16.3% the prior year.
Abbott Labs's revenue grew 5.7% year-over-year to $44.3B, a solid pace of expansion. This earns a growth score of 42/100.
Abbott Labs carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
Abbott Labs's current ratio of 1.58 is below the typical benchmark, resulting in a score of 27/100. However, the company holds substantial cash reserves (52% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Abbott Labs has a free cash flow margin of 16.7%, earning a moderate score of 64/100. The company generates positive cash flow after capital investments, but with room for improvement.
Abbott Labs's ROE of 12.5% shows moderate profitability relative to equity, earning a score of 50/100. This is down from 28.1% the prior year.
Abbott Labs scores 4.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($153.9B) relative to total liabilities ($34.6B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Abbott Labs passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Abbott Labs generates $1.47 in operating cash flow ($9.6B OCF vs $6.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Abbott Labs earns $16.3 in operating income for every $1 of interest expense ($8.1B vs $493.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Abbott Labs generated $44.3B in revenue in fiscal year 2025. This represents an increase of 5.7% from the prior year.
Abbott Labs's EBITDA was $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.2% from the prior year.
Abbott Labs reported $6.5B in net income in fiscal year 2025. This represents a decrease of 51.3% from the prior year.
Abbott Labs earned $3.72 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 51.3% from the prior year.
Cash & Balance Sheet
Abbott Labs generated $7.4B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.4% from the prior year.
Abbott Labs held $8.5B in cash against $9.9B in long-term debt as of fiscal year 2025.
Abbott Labs paid $2.40 per share in dividends in fiscal year 2025. This represents an increase of 7.1% from the prior year.
Abbott Labs had 1.74B shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.
Margins & Returns
Abbott Labs's gross margin was 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.
Abbott Labs's operating margin was 18.2% in fiscal year 2025, reflecting core business profitability. This is up 1.9 percentage points from the prior year.
Abbott Labs's net profit margin was 14.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 17.2 percentage points from the prior year.
Abbott Labs's ROE was 12.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.6 percentage points from the prior year.
Capital Allocation
Abbott Labs invested $2.9B in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Abbott Labs spent $893.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 31.0% from the prior year.
Abbott Labs invested $2.2B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 1.6% from the prior year.
ABT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2B-2.6% | $11.5B+0.8% | $11.4B+2.0% | $11.1B+7.6% | $10.4B-5.6% | $11.0B+3.2% | $10.6B+2.5% | $10.4B |
| Cost of Revenue | $4.9B-0.7% | $4.9B-3.0% | $5.1B+4.6% | $4.9B+8.6% | $4.5B-9.6% | $4.9B+5.2% | $4.7B+2.1% | $4.6B |
| Gross Profit | $6.3B-4.0% | $6.5B+3.9% | $6.3B+0.1% | $6.3B+6.8% | $5.9B-2.4% | $6.0B+1.6% | $5.9B+2.8% | $5.8B |
| R&D Expenses | $767.0M+4.4% | $735.0M-4.0% | $766.0M+5.7% | $725.0M+1.3% | $716.0M-4.4% | $749.0M+5.0% | $713.0M+2.1% | $698.0M |
| SG&A Expenses | $3.7B+19.5% | $3.1B+2.6% | $3.1B-1.3% | $3.1B+1.0% | $3.1B+5.3% | $2.9B+0.4% | $2.9B-1.4% | $2.9B |
| Operating Income | $1.3B-40.2% | $2.3B+9.4% | $2.1B+0.2% | $2.1B+21.2% | $1.7B-11.4% | $1.9B+2.8% | $1.9B+11.4% | $1.7B |
| Interest Expense | $174.0M+45.0% | $120.0M-0.8% | $121.0M0.0% | $121.0M-7.6% | $131.0M-3.7% | $136.0M-4.2% | $142.0M+1.4% | $140.0M |
| Income Tax | $372.0M-36.1% | $582.0M+8.6% | $536.0M+44.5% | $371.0M-18.1% | $453.0M+106.3% | -$7.2B-2548.6% | $294.0M-3.6% | $305.0M |
| Net Income | $1.1B-39.4% | $1.8B+8.0% | $1.6B-7.6% | $1.8B+34.3% | $1.3B-85.6% | $9.2B+460.7% | $1.6B+26.4% | $1.3B |
| EPS (Diluted) | $0.61 | N/A | $0.94-6.9% | $1.01+32.9% | $0.76 | N/A | $0.94+27.0% | $0.74 |
ABT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $110.4B+27.3% | $86.7B+3.0% | $84.2B+0.2% | $84.0B+3.1% | $81.4B0.0% | $81.4B+9.5% | $74.4B+1.8% | $73.0B |
| Current Assets | $25.5B-1.9% | $26.0B+4.7% | $24.8B+1.5% | $24.5B+5.7% | $23.2B-2.1% | $23.7B-0.6% | $23.8B+3.0% | $23.1B |
| Cash & Equivalents | $6.8B-20.2% | $8.5B+13.5% | $7.5B+8.1% | $7.0B+6.4% | $6.5B-14.2% | $7.6B+0.8% | $7.6B+8.2% | $7.0B |
| Inventory | $7.0B+7.7% | $6.5B-3.3% | $6.7B-3.5% | $7.0B+4.7% | $6.6B+7.2% | $6.2B-9.1% | $6.8B0.0% | $6.8B |
| Accounts Receivable | $8.2B+3.5% | $7.9B-2.6% | $8.1B+2.1% | $8.0B+8.8% | $7.3B+5.8% | $6.9B-1.8% | $7.1B+2.9% | $6.9B |
| Goodwill | $35.2B+46.5% | $24.0B+0.3% | $24.0B+0.1% | $24.0B+2.5% | $23.4B+1.1% | $23.1B-2.3% | $23.7B+1.5% | $23.3B |
| Total Liabilities | $58.4B+68.8% | $34.6B+4.1% | $33.2B-0.6% | $33.4B+2.4% | $32.6B-3.3% | $33.8B-2.3% | $34.6B+2.6% | $33.7B |
| Current Liabilities | $18.4B+11.4% | $16.5B+13.1% | $14.6B+8.5% | $13.4B+3.3% | $13.0B-8.1% | $14.2B-5.0% | $14.9B+8.3% | $13.8B |
| Long-Term Debt | $29.6B+199.5% | $9.9B-14.7% | $11.6B-10.3% | $12.9B+1.5% | $12.7B+0.9% | $12.6B-1.6% | $12.8B-2.4% | $13.1B |
| Total Equity | $52.1B-0.1% | $52.1B+2.3% | $51.0B+0.8% | $50.6B+3.6% | $48.8B+2.4% | $47.7B+19.8% | $39.8B+1.2% | $39.3B |
| Retained Earnings | $50.0B+0.4% | $49.8B+1.4% | $49.1B+1.3% | $48.5B+1.6% | $47.7B+1.0% | $47.3B+21.0% | $39.1B+1.8% | $38.4B |
ABT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.3B-60.3% | $3.3B+18.9% | $2.8B+36.2% | $2.0B+44.5% | $1.4B-50.6% | $2.9B+6.0% | $2.7B+38.0% | $2.0B |
| Capital Expenditures | $399.0M-42.1% | $689.0M+38.9% | $496.0M-1.2% | $502.0M+3.7% | $484.0M-32.8% | $720.0M+29.5% | $556.0M+4.3% | $533.0M |
| Free Cash Flow | $916.0M-65.1% | $2.6B+14.6% | $2.3B+48.3% | $1.5B+65.6% | $933.0M-56.6% | $2.1B0.0% | $2.1B+50.6% | $1.4B |
| Investing Cash Flow | -$20.3B-2126.1% | -$913.0M-99.8% | -$457.0M+21.5% | -$582.0M-23.8% | -$470.0M+45.7% | -$866.0M-45.8% | -$594.0M-31.1% | -$453.0M |
| Financing Cash Flow | $17.3B+1339.3% | -$1.4B+20.6% | -$1.8B-60.4% | -$1.1B+46.6% | -$2.1B-10.4% | -$1.9B-18.1% | -$1.6B-99.2% | -$791.0M |
| Dividends Paid | $1.1B+6.6% | $1.0B-0.1% | $1.0B+0.2% | $1.0B+0.3% | $1.0B+7.1% | $958.0M-0.2% | $960.0M-0.1% | $961.0M |
| Share Buybacks | $180.0M-40.4% | $302.0M-1.0% | $305.0M+4983.3% | $6.0M-97.9% | $280.0M-11.1% | $315.0M-58.1% | $751.0M+24933.3% | $3.0M |
ABT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.2%-0.8pp | 57.0%+1.7pp | 55.4%-1.1pp | 56.4%-0.4pp | 56.9%+1.9pp | 55.0%-0.9pp | 55.8%+0.2pp | 55.6% |
| Operating Margin | 12.0%-7.6pp | 19.6%+1.5pp | 18.1%-0.3pp | 18.4%+2.1pp | 16.3%-1.1pp | 17.4%-0.1pp | 17.5%+1.4pp | 16.1% |
| Net Margin | 9.7%-5.8pp | 15.5%+1.0pp | 14.5%-1.5pp | 16.0%+3.2pp | 12.8%-71.3pp | 84.1%+68.6pp | 15.5%+2.9pp | 12.6% |
| Return on Equity | 2.1%-1.3pp | 3.4%+0.2pp | 3.2%-0.3pp | 3.5%+0.8pp | 2.7%-16.6pp | 19.4%+15.2pp | 4.1%+0.8pp | 3.3% |
| Return on Assets | 1.0%-1.1pp | 2.1%+0.1pp | 1.9%-0.2pp | 2.1%+0.5pp | 1.6%-9.7pp | 11.3%+9.1pp | 2.2%+0.4pp | 1.8% |
| Current Ratio | 1.39-0.2 | 1.58-0.1 | 1.70-0.1 | 1.82+0.0 | 1.78+0.1 | 1.67+0.1 | 1.60-0.1 | 1.68 |
| Debt-to-Equity | 0.57+0.4 | 0.19-0.0 | 0.23-0.0 | 0.260.0 | 0.260.0 | 0.26-0.1 | 0.32-0.0 | 0.33 |
| FCF Margin | 8.2%-14.7pp | 22.9%+2.8pp | 20.2%+6.3pp | 13.9%+4.9pp | 9.0%-10.6pp | 19.6%-0.6pp | 20.2%+6.5pp | 13.8% |
Similar Companies
Frequently Asked Questions
What is Abbott Labs's annual revenue?
Abbott Labs (ABT) reported $44.3B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Abbott Labs's revenue growing?
Abbott Labs (ABT) revenue grew by 5.7% year-over-year, from $42.0B to $44.3B in fiscal year 2025.
Is Abbott Labs profitable?
Yes, Abbott Labs (ABT) reported a net income of $6.5B in fiscal year 2025, with a net profit margin of 14.7%.
What is Abbott Labs's EBITDA?
Abbott Labs (ABT) had EBITDA of $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Abbott Labs have?
As of fiscal year 2025, Abbott Labs (ABT) had $8.5B in cash and equivalents against $9.9B in long-term debt.
What is Abbott Labs's gross margin?
Abbott Labs (ABT) had a gross margin of 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Abbott Labs's operating margin?
Abbott Labs (ABT) had an operating margin of 18.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Abbott Labs's net profit margin?
Abbott Labs (ABT) had a net profit margin of 14.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Abbott Labs pay dividends?
Yes, Abbott Labs (ABT) paid $2.40 per share in dividends during fiscal year 2025.
What is Abbott Labs's return on equity (ROE)?
Abbott Labs (ABT) has a return on equity of 12.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Abbott Labs's free cash flow?
Abbott Labs (ABT) generated $7.4B in free cash flow during fiscal year 2025. This represents a 16.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Abbott Labs's operating cash flow?
Abbott Labs (ABT) generated $9.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Abbott Labs's total assets?
Abbott Labs (ABT) had $86.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Abbott Labs's capital expenditures?
Abbott Labs (ABT) invested $2.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Abbott Labs spend on research and development?
Abbott Labs (ABT) invested $2.9B in research and development during fiscal year 2025.
What is Abbott Labs's current ratio?
Abbott Labs (ABT) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.
What is Abbott Labs's debt-to-equity ratio?
Abbott Labs (ABT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Abbott Labs's return on assets (ROA)?
Abbott Labs (ABT) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Abbott Labs's Altman Z-Score?
Abbott Labs (ABT) has an Altman Z-Score of 4.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Abbott Labs's Piotroski F-Score?
Abbott Labs (ABT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Abbott Labs's earnings high quality?
Abbott Labs (ABT) has an earnings quality ratio of 1.47x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Abbott Labs cover its interest payments?
Abbott Labs (ABT) has an interest coverage ratio of 16.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Abbott Labs?
Abbott Labs (ABT) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.